Compare AbCellera Biologics Inc (ABCL) vs Victoria's Secret & Co (VSXY) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Victoria's Secret (VSXY) trades at $78.25, up 2.01% with strong momentum as the stock benefits from international expansion and improved fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.60 surpassing the $0.32 estimate. Technical indicators show a neutral overall signal while the stock trades near pivot point resistance at $78. Analyst consensus remains bullish with a $88.56 price target representing 13% upside potential.

The outlook appears positive with international sales growing 44.9% in Q1 2026 and margin recovery underway, though risks include competitive pressures and execution challenges in global expansion. With improving cash flow projections and shareholder support for management's strategy, VSXY offers growth potential but requires monitoring of consumer spending trends and inventory management.